Recro pharma, inc. (REPH)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenue

99,219

77,347

71,834

69,337

-

-

-

Revenue

-

-

-

-

51,952

-

-

Operating expenses:
Cost of sales (excluding amortization of intangible assets)

50,981

43,160

38,193

37,152

28,054

-

-

Research and development

-

4,402

4,460

33,278

12,281

7,874

543

Selling, general and administrative

19,909

14,437

14,324

-

-

-

-

General and administrative

-

-

-

12,742

13,017

3,997

546

Amortization of intangible assets

2,583

2,583

2,583

2,583

1,884

-

-

Change in warrant valuation

2,116

284

9

-373

-1,560

-

-

Change in contingent consideration valuation

-

-

-

9,728

5,246

-

-

Total operating expenses

75,589

64,866

59,569

95,110

58,922

-

-

Operating income from continuing operations

23,630

12,481

12,265

-31,312

-12,518

-

-

Operating income (loss) from continuing operations

-

-

-

-25,773

-6,970

-

-

Total operating expenses

-

-

-

-

-

11,871

1,089

Other income (expense):
Interest income

801

643

369

49

12

10

0

Interest expense

19,806

8,756

12,034

5,588

5,560

4,272

868

Income from continuing operations before income taxes

4,625

4,368

600

-

-

-

-

Income tax expense

0

17,436

7,317

-1,107

-15,551

-

-

Net income (loss) from continuing operations

4,625

-13,068

-6,717

-

-

-

-

Loss on discontinued operations

-23,255

-66,655

-43,365

-

-

-

-

Other income (expense), net

-

-

-

-

-

-4,262

-868

Net loss

-18,630

-79,723

-50,082

-30,205

3,033

-16,134

-1,957

Per share information:
Net income (loss) per share from continuing operations, basic

0.21

-0.64

-0.35

-

-

-

-

Net loss per share from discontinued operations, basic

-1.04

-3.26

-2.28

-

-

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

1,270

440

Net loss

-

-

-

-

-

-17,404

-2,398

Net loss per share of common stock, basic and diluted

-

-

-

-2.82

-

-2.79

-15.41

Weighted average common shares outstanding, basic and diluted

-

-

-

10,721

-

6,238

155

Net loss per share, basic

-0.83

-3.90

-2.63

-

0.36

-

-

Weighted average common shares outstanding, basic

22,414

20,465

19,070

-

8,491

-

-

Net income (loss) per share from continuing operations, diluted

0.20

-0.64

-0.35

-

-

-

-

Net loss per share from discontinued operations, diluted

-0.99

-3.26

-2.28

-

-

-

-

Net loss per share, diluted

-0.79

-3.90

-2.63

-

0.21

-

-

Weighted average common shares outstanding, diluted

23,608

20,465

19,070

-

8,749

-

-

Net loss

-18,630

-79,723

-50,082

-30,205

3,033

-

-

Other comprehensive loss:
Unrealized gain/(loss) on available-for-sale securities

-

1

-1

-

-

-

-

Comprehensive loss

-18,630

-79,722

-50,083

-30,205

3,033

-

-